Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Administration of albuterol Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Asthma
Interventions: T-Piece Nebulizer, Breath-Enhanced Nebulizer, Albuterol, Pre-Treatment Spirometry Measurement, Post-Treatment Spirometry Measurement; Device · Drug · Procedure
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 6 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: hypertonic saline, standard saline; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Preeclampsia
Interventions: Transthoracic Echocardiography; Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Submental Fat
Interventions: LIPO-202, Placebo for LIPO-202; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Placebo, Albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 94
States / cities: Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: Asthma
Interventions: Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF; Drug
Lead sponsor: Novartis; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more

Conditions: Asthma
Interventions: FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 11,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 350
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Albuterol/salbutamol, Ipratropium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Asthma
Interventions: Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product; Drug
Lead sponsor: Amneal Ireland Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Brookhaven, New York

Conditions: Reactive Airways Disease (RAD)
Interventions: Levalbuterol HCl Inhalation Solution, Albuterol HCl Inhalation Solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 32
States / cities: Little Rock, Arkansas • Corona, California • Englewood, California + 29 more

Conditions: Asthma
Interventions: Nebulized Budesonide, Usual care (albuterol with or without oral steroid); Drug
Lead sponsor: Deborah Gentile; Other
Eligibility: 1 Year to 8 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Bellevue, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Asthma Exacerbation
Interventions: Aeroneb nebulizer, Small volume jet nebulizer; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: COPD Exacerbation
Interventions: Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic); Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more

Conditions: Asthma
Interventions: Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 75
States / cities: Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Asthma
Interventions: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 3
States / cities: Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri

Search by objective public record fields.

Tiotropium/Salmeterol Inhalation Powder in COPD

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Nebulized Hypertonic Saline for Inpatient Use in COPD

Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Fall Epidemic Viral Pediatric Study

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)

Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children

Effectiveness of the Aeroneb in Acute Severe Asthma

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma